How Pandemic-Era Mortality Assumptions Still Show Up in Offers Today
Life settlement pricing is ultimately a timing and cash-flow problem: investors estimate how long premiums will need to be paid, when a death benefit is likely to be collected, and what return is reasonable for the risk. During the COVID era, mortality experience shifted quickly, and that shift didn’t just change headlines—it changed how longevity risk is modeled, stress-tested, and priced.
Even as excess mortality has moderated from peak pandemic years, many pricing teams still treat COVID-era data as a “regime change” that increased uncertainty. The result in today’s market is less about one specific table and more about how buyers build buffers, compare life expectancy inputs, and handle scenarios where mortality patterns differ from pre-2020 expectations.
Where “Mortality Tables” Fit in a Life Settlement Price
Unlike traditional life insurance pricing, life settlements typically rely heavily on life expectancy (LE) assessments and portfolio modeling rather than a single published mortality table. Still, mortality tables and improvement scales matter because they influence the baseline assumptions used by many actuarial models and analytical frameworks.
In practice, “COVID-era mortality tables” affects pricing through three channels:
Life expectancy providers: baseline mortality assumptions and calibration choices influence LE estimates.
Investor models: discounting and stress testing often reference mortality and improvement frameworks.
Risk buffers: uncertainty increases required returns and widens bid spreads.
The Two Biggest Pricing Effects Since COVID
1) More Uncertainty in Timing Means More Conservative Pricing
COVID highlighted that mortality can change quickly due to external shocks, healthcare system strain, and population-level health trends. Buyers responded by increasing the emphasis on stress testing: what happens if insureds live longer than expected, if mortality normalizes, or if improvements resume more strongly than modeled?
When uncertainty rises, investors typically protect themselves with:
- higher required returns (which pushes offers down)
- more conservative longevity scenarios
- greater scrutiny of premium adequacy and lapse risk
Even if a policy “looks good” under a base-case LE, the price may reflect the downside scenarios more heavily than it did pre-pandemic.
2) Life Expectancy Inputs Became a Negotiation Point
Because different LE providers can respond to changing mortality trends at different speeds, buyers often compare multiple reports and focus on the methodology, not just the number. In the post-COVID environment, many investors are less willing to anchor to a single LE result—especially on cases where a small change in assumed survival time materially affects premium outflows and portfolio returns.
Tip: In the current market, “one LE report” often produces “one cautious offer.” Multiple credible inputs and clear documentation more often produce competitive bidding.
This doesn’t mean every case needs multiple reports, but it does mean buyers are more sensitive to how the LE is supported and whether it holds up under conservative stress assumptions.
Why Pricing Didn’t Simply “Go Up” Because Mortality Increased
A common assumption is that higher mortality automatically increases settlement values because investors might expect shorter durations. In reality, the pandemic effect created both short-term mortality spikes and long-term modeling questions. Buyers worry about:
- whether mortality reverts toward pre-pandemic patterns
- whether lingering excess mortality persists in certain age bands
- whether future medical advances shift longevity again
- whether premium costs and policy performance create higher carry risk over longer durations
So instead of a simple “prices rise,” the market often responded with tighter underwriting, more documentation requests, and more scenario-based pricing.
Case Types Most Affected by COVID-Era Assumption Shifts
Early-Duration or Recently Issued Policies
Newer policies already face heightened scrutiny due to claim risk considerations. Add post-COVID modeling uncertainty, and buyers may lean even more conservative, especially if documentation is incomplete or application/medical records raise questions.
Policies With High Carry Cost or Thin Funding
If a policy requires heavy premiums, small changes in assumed survival time can dramatically affect returns. Post-COVID, many investors apply more conservative duration assumptions to protect against longevity drift, which can pressure offers on high-premium cases.
Complex UL, VUL, and IUL Structures
For flexible-premium policies, buyers must model not only longevity but also policy mechanics and performance assumptions. When longevity uncertainty increases, the importance of premium adequacy and lapse risk rises right alongside it.
How Policyholders and Advisors Can Respond to Today’s Pricing Reality
- Build a “clean file” early: medical records, policy pages, premium history, in-force illustration, and loan details reduce buyer discounting.
- Address premium sustainability: show a credible premium-to-keep-in-force plan so longevity stress tests don’t break the case.
- Consider multiple LE perspectives: especially when offers vary widely or the insured profile is complex.
- Push for assumption transparency: ask buyers what survival and premium assumptions drove their bid and compare on a like-for-like basis.
The Takeaway: COVID Didn’t Rewrite Pricing—It Raised the Standard for Confidence
COVID-era mortality experience increased the market’s focus on uncertainty, stress testing, and defensible longevity assumptions. In today’s environment, the best pricing outcomes tend to come from policies that are easy to model and service, supported by strong documentation, and presented with clear premium sustainability and credible life expectancy support. The “mortality table” isn’t the whole story—but the post-COVID mindset absolutely influences how offers are set.
FAQ
Do life settlement buyers use official mortality tables to price policies?
Buyers typically rely heavily on life expectancy assessments and portfolio cash-flow modeling. Mortality tables and improvement concepts still matter because they influence baselines and stress-test frameworks, but pricing is rarely driven by a single published table alone.
Did COVID increase life settlement offers because mortality increased?
Not in a simple, uniform way. While short-term mortality spikes can affect assumptions, the larger impact was increased uncertainty and more conservative scenario testing, which can reduce offers or widen bid ranges depending on the case.
Why do investors request multiple life expectancy reports more often now?
Because different methodologies can respond to changing mortality patterns differently, and small changes in assumed duration can materially change premium costs and returns. Multiple inputs can improve pricing confidence.
How does excess mortality “declining” affect current pricing?
As excess mortality moderates, some models may trend toward more normalized assumptions, but many buyers still keep stronger stress tests and buffers due to the experience of rapid change during the pandemic.
Which policies are most sensitive to COVID-era assumption changes?
Policies with high premium carry costs, thin funding, complex UL/VUL/IUL mechanics, or cases where underwriting is documentation-heavy tend to be most sensitive because pricing is highly dependent on duration and stability assumptions.
What’s the best way to improve pricing in this environment?
Reduce uncertainty: provide complete documentation, demonstrate premium sustainability, clarify loans and policy mechanics, and ensure life expectancy support is credible and consistent.
Does this topic affect escrow or closing mechanics?
Indirectly. Greater diligence and more conservative underwriting can extend timelines and increase documentation requirements. A well-prepared file helps avoid delays and last-minute pricing changes.
Should a policyholder wait for “better market conditions” if offers seem low?
It depends on premium burden, lapse risk, and liquidity needs. If the policy is expensive or at risk of lapse, waiting can reduce leverage. A net comparison of keep vs sell vs surrender often helps decide.
Are COVID-era effects the same for every age group?
No. Mortality patterns have varied by age, health, and time period, which is part of why investors rely on case-specific medical underwriting and stress testing rather than a single broad assumption.
Can better policy funding strategy offset longevity uncertainty?
Often yes. If a policy is clearly sustainable with a predictable premium schedule, investors can tolerate longevity uncertainty more easily because the carry-cost risk is reduced.